Publication:
Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group

Issued Date

2017-04-05

Resource Type

Article

ISSN

14752875

DOI

10.1186/s12936-017-1784-1

Other identifier(s)

2-s2.0-85016978562

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

Malaria Journal. Vol.16, No.1 (2017)

Suggested Citation

Kamala Thriemer, Benedikt Ley, Albino Bobogare, Lek Dysoley, Mohammad Shafiul Alam, Ayodhia P. Pasaribu, Jetsumon Sattabongkot, Elodie Jambert, Gonzalo J. Domingo, Robert Commons, Sarah Auburn, Jutta Marfurt, Angela Devine, Mohammad M. Aktaruzzaman, Nayeem Sohel, Rinzin Namgay, Tobgyel Drukpa, Surender Nath Sharma, Elvieda Sarawati, Iriani Samad, Minerva Theodora, Simone Nambanya, Sonesay Ounekham, Rose Nanti Binti Mudin, Garib Da Thakur, Leo Sora Makita, Raffy Deray, Sang Eun Lee, Leonard Boaz, Manjula N. Danansuriya, Santha D. Mudiyanselage, Nipon Chinanonwait, Suravadee Kitchakarn, Johnny Nausien, Esau Naket, Thang Ngo Duc, Ha Do Manh, Young S. Hong, Qin Cheng, Jack S. Richards, Rita Kusriastuti, Ari Satyagraha, Rintis Noviyanti, Xavier C. Ding, Wasif Ali Khan, Ching Swe Phru, Zhu Guoding, Gao Qi, Akira Kaneko, Olivo Miotto, Wang Nguitragool, Wanlapa Roobsoong, Katherine Battle, Rosalind E. Howes, Arantxa Roca-Feltrer, Stephan Duparc, Ipsita Pal Bhowmick, Enny Kenangalem, Jo Anne Bibit, Alyssa Barry, David Sintasath, Rabindra Abeyasinghe, Carol H. Sibley, James McCarthy, Lorenz Von Seidlein, J. Kevin Baird, Ric N. Price Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group. Malaria Journal. Vol.16, No.1 (2017). doi:10.1186/s12936-017-1784-1 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/42843

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group

Author(s)

Kamala Thriemer
 Benedikt Ley
 Albino Bobogare
 Lek Dysoley
 Mohammad Shafiul Alam
 Ayodhia P. Pasaribu
 Jetsumon Sattabongkot
 Elodie Jambert
 Gonzalo J. Domingo
 Robert Commons
 Sarah Auburn
 Jutta Marfurt
 Angela Devine
 Mohammad M. Aktaruzzaman
 Nayeem Sohel
 Rinzin Namgay
 Tobgyel Drukpa
 Surender Nath Sharma
 Elvieda Sarawati
 Iriani Samad
 Minerva Theodora
 Simone Nambanya
 Sonesay Ounekham
 Rose Nanti Binti Mudin
 Garib Da Thakur
 Leo Sora Makita
 Raffy Deray
 Sang Eun Lee
 Leonard Boaz
 Manjula N. Danansuriya
 Santha D. Mudiyanselage
 Nipon Chinanonwait
 Suravadee Kitchakarn
 Johnny Nausien
 Esau Naket
 Thang Ngo Duc
 Ha Do Manh
 Young S. Hong
 Qin Cheng
 Jack S. Richards
 Rita Kusriastuti
 Ari Satyagraha
 Rintis Noviyanti
 Xavier C. Ding
 Wasif Ali Khan
 Ching Swe Phru
 Zhu Guoding
 Gao Qi
 Akira Kaneko
 Olivo Miotto
 Wang Nguitragool
 Wanlapa Roobsoong
 Katherine Battle
 Rosalind E. Howes
 Arantxa Roca-Feltrer
 Stephan Duparc
 Ipsita Pal Bhowmick
 Enny Kenangalem
 Jo Anne Bibit
 Alyssa Barry
 David Sintasath
 Rabindra Abeyasinghe
 Carol H. Sibley
 James McCarthy
 Lorenz Von Seidlein
 J. Kevin Baird
 Ric N. Price

Other Contributor(s)

Menzies School of Health Research
 National Vector Borne Disease Control Programme
 National Center for Parasitology, Entomology and Malaria Control
 National Institute of Public Health
 International Centre for Diarrheal Diseases and Research
 Universitas Sumatera Utara
 Mahidol University
 Medicines for Malaria Venture (MMV)
 PATH
 Mahidol-Oxford Tropical Medicine Research Unit
 Nuffield Department of Clinical Medicine
 Ministry of Health and Family Welfare
 Ministry of Health in Bhutan
 Ministry of Health and Family Welfare
 National Malaria Control Program
 National Center for Entomology Parasitology and Malaria Control
 Kementerian Kesihatan Malaysia
 Minister for Health and Population Nepal
 National Malaria Control Programme
 Department of Health Manila
 Korea Centers for Disease Control & Prevention
 Ministry of Health Colombo
 Thailand Ministry of Public Health
 National Malaria Control Programme
 National Institute of Malaria, Parasitology, and Entomology (NIMPE)
 Access Bio Inc
 Australian Army Malaria Institute
 Burnet Institute
 Ministry of Health, Republic of Indonesia
 Indonesian Medical Association
 Eijkman Institute of Molecular Biology
 FIND
 Jiangsu Institute of Parasitic Diseases
 Karolinska Institutet
 Osaka City University
 Wellcome Trust Centre for Human Genetics
 Wellcome Trust Sanger Institute
 Malaria Consortium
 Indian Council of Medical Research
 Yayasan Pengembangan Kesehatan dan Masyarakat Papua Timika
 Gokila
 Walter and Eliza Hall Institute of Medical Research
 University of Melbourne
 United States Agency for International Development
 Organisation Mondiale de la Santé
 WWARN
 University of Washington, Seattle
 QIMR Berghofer Medical Research Institute
 Eijkman-Oxford Clinical Research Unit

Abstract

© 2017 The Author(s). The delivery of safe and effective radical cure for Plasmodium vivax is one of the greatest challenges for achieving malaria elimination from the Asia-Pacific by 2030. During the annual meeting of the Asia Pacific Malaria Elimination Network Vivax Working Group in October 2016, a round table discussion was held to discuss the programmatic issues hindering the widespread use of primaquine (PQ) radical cure. Participants included 73 representatives from 16 partner countries and 33 institutional partners and other research institutes. In this meeting report, the key discussion points are presented and grouped into five themes: (i) current barriers for glucose-6-phosphate deficiency (G6PD) testing prior to PQ radical cure, (ii) necessary properties of G6PD tests for wide scale deployment, (iii) the promotion of G6PD testing, (iv) improving adherence to PQ regimens and (v) the challenges for future tafenoquine (TQ) roll out. Robust point of care (PoC) G6PD tests are needed, which are suitable and cost-effective for clinical settings with limited infrastructure. An affordable and competitive test price is needed, accompanied by sustainable funding for the product with appropriate training of healthcare staff, and robust quality control and assurance processes. In the absence of quantitative PoC G6PD tests, G6PD status can be gauged with qualitative diagnostics, however none of the available tests is currently sensitive enough to guide TQ treatment. TQ introduction will require overcoming additional challenges including the management of severely and intermediately G6PD deficient individuals. Robust strategies are needed to ensure that effective treatment practices can be deployed widely, and these should ensure that the caveats are outweighed by the benefits of radical cure for both the patients and the community. Widespread access to quality controlled G6PD testing will be critical.

Keyword(s)

Immunology and Microbiology

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/42843

Collections

Scopus 2016-2017